Renaissance Technologies LLC Purchases 1,414,746 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Renaissance Technologies LLC lifted its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 716.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,612,146 shares of the company's stock after buying an additional 1,414,746 shares during the period. Renaissance Technologies LLC owned approximately 0.55% of Lyell Immunopharma worth $1,032,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of LYEL. Wells Fargo & Company MN increased its stake in Lyell Immunopharma by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock valued at $60,000 after acquiring an additional 20,542 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Lyell Immunopharma by 102.8% in the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock valued at $75,000 after purchasing an additional 59,182 shares in the last quarter. RPO LLC bought a new position in shares of Lyell Immunopharma in the 4th quarter valued at $42,000. Jane Street Group LLC raised its holdings in shares of Lyell Immunopharma by 63.7% during the 3rd quarter. Jane Street Group LLC now owns 287,717 shares of the company's stock worth $397,000 after buying an additional 111,917 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Lyell Immunopharma by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company's stock worth $2,648,000 after buying an additional 117,303 shares during the last quarter. 66.05% of the stock is currently owned by institutional investors.

Insider Activity

In other Lyell Immunopharma news, CFO Charles W. Newton purchased 200,000 shares of the business's stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $0.56 per share, for a total transaction of $112,000.00. Following the completion of the acquisition, the chief financial officer now owns 200,000 shares in the company, valued at approximately $112,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Richard Klausner acquired 158,000 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The stock was bought at an average price of $0.60 per share, with a total value of $94,800.00. Following the completion of the acquisition, the director now directly owns 843,365 shares of the company's stock, valued at $506,019. This trade represents a 23.05 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 768,640 shares of company stock valued at $449,508 over the last quarter. 25.10% of the stock is owned by company insiders.

Lyell Immunopharma Trading Down 4.3 %

Lyell Immunopharma stock traded down $0.02 during mid-day trading on Tuesday, reaching $0.42. The company had a trading volume of 576,445 shares, compared to its average volume of 1,038,293. The business has a fifty day simple moving average of $0.52 and a 200 day simple moving average of $0.70. The company has a market cap of $122.77 million, a P/E ratio of -0.53 and a beta of -0.25. Lyell Immunopharma, Inc. has a fifty-two week low of $0.39 and a fifty-two week high of $2.88.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). The firm had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Research analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "neutral" rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research report on Wednesday, April 16th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.